|
|
|
|
Kaiser Study Finds Link between First-line Tenofovir (Viread) Use and Kidney Impairment
People with HIV have been shown to have higher rates of kidney disease.In some cases, this is related to HIV infection itself (HIV-associated nephropathy), but antiretroviral drugs may also play a role. The nucleotide reverse transcriptase inhibitor...
|
|
|
Less resistance with FTC than 3TC when combined with tenofovir
Amongst patients experiencing a rebound in viral load, those taking 3TC (lamivudine, Epivir) in combination with tenofovir (Viread) were more likely than those taking FTC (emtricitabine, Emtriva) and tenofovir to develop a number of key resistance...
|
|
|
Gilead Sciences Gets Notification of ANDA Filing for Viread
Gilead Sciences, Inc.has announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Gilead Sciences Gets Notification of ANDA Filing for Viread.<...
|
|
|
Teva files ANDA for generic version of HIV drug
FOSTER CITY,Calif.(Feb. 1) Teva is hoping to release its version of an HIV drug before the drugs patents expire. Gilead Sciences announced that it had received notice that Teva had applied for regulatory approval with the Food and Drug Administration for...
|
|
|
Gilead Sciences Announces Notification of ANDA Filing for Viread
- Gilead Sciences, Inc.(Nasdaq:GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting...
|
|
|
Gilead Sciences Announces Notification of ANDA Filing for Viread ,
(BUSINESS WIRE) Gilead Sciences, Inc.(Nasdaq:GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA)...
|
|
|
Gilead Sciences Announces Notification Of ANDA Filing For Viread(R)
Gilead Sciences, Inc.(Nasdaq:GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting...
|
|
|
Gilead Fourth Quarter Profit Rises 43% on Atripla Sales
FOSTER CITY, Calif.(AP) ' Gilead Sciences Inc. said Tuesday its profit climbed 43 percent in the fourth quarter due to rising sales of its three-in-one HIV drug Atripla. The company said sales of Atripla, which was approved in the U.S. in July 2006,...
|
|
|
Markets in Brief
That's been the question on the lips of every forex player for months and yesterday Bank of Israel Governor Stanley Fischer answered it.Speaking to Reuters Insider television at the World Economic Forum in Davos, Fischer said he hoped to phase out...
|
|
|
Gilead Sciences Announces Notification of ANDA Filing for Viread
Gilead Sciences, Inc.announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application to the U.S. Gilead Sciences Announces Notification of ANDA Filing for Viread.
|
|
|
Epidemiology of HIV/HBV Coinfection in a U.S. Military Cohort
Helen Chun and colleagues with the Infectious Disease Clinical Research Program looked at the epidemiologic trends of HBV infection in over the course of 20 years.Because HIV and HBV have overlapping transmission routes, many people are infected with both...
|
|
|
Medical News: Gilead Sciences Announces Notification Of ANDA Filing For Viread(R)
Gilead Sciences, Inc.(Nasdaq:GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting...
|
|
|
Gilead announces notification of ANDA filing for Viread
- US biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported yesterday the receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals (NASDAQ: TEVA) submitted an Abbreviated New Drug Application (ANDA) to the US Food...
|
|
|
Gilead announces notification of ANDA filing for Viread
- US biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported yesterday the receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals (NASDAQ: TEVA) submitted an Abbreviated New Drug Application (ANDA) to the US Food...
|
|
|
Gilead Sciences Announces Notification of ANDA Filing for Viread
Gilead Sciences Announces Notification of ANDA Filing for Viread FOSTER CITY, Calif.- (BUSINESS WIRE) - Gilead Sciences, Inc. (Nasdaq:GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals...
|
|
|
Gilead Sciences gibt Avisierung ber ANDA-Einreichung fr Viread bekannt
Gilead Sciences, Inc.(NASDAQ: GILD), hat heute den Empfang eines Schreibens (Paragraph IV Certification Notice Letter) bekannt gegeben, gem dem Teva Pharmaceuticals bei der US-amerikanischen Lebens- und Arzneimittelzulassungsbehrde FDA einen abgekrzten...
|
|
|
Gilead Sciences (GILD) Announces that Teva Pharma (TEVA) Files ANDA with U.S. FDA for Generic Form of Viread
Gilead Sciences, Inc.(NASDAQ: GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals (NASDAQ: TEVA) submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA)...
|
|
|
Gilead Sciences reviewing Notice Letter regarding Teva Pharmaceuticals' generic Viread ANDA
Gilead Sciences, Inc.(Nasdaq:GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting...
|
|
|
Gilead Sciences Announces Notification of ANDA Filing for Viread
FOSTER CITY, Calif.(BUSINESS WIRE) Gilead Sciences, Inc.(Nasdaq:GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug...
|
|
|
Gilead Sciences Announces Notification of ANDA Filing for Viread
FOSTER CITY, Calif.-- (BUSINESS WIRE) -- Gilead Sciences, Inc.(Nasdaq:GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and...
|
|
|
Gilead Sciences Announces Notification of ANDA Filing for Viread
- - Submitted by admin on 1/27/2010 @ 8:20 PM Companies mentioned in this article: FOSTER CITY, Calif.-- (BUSINESS WIRE) -- (Nasdaq:GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an...
|
|
|
Gilead Sciences Announces Notification of ANDA Filing for Viread
Gilead Sciences, Inc.GILD today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to...
|
|
|
Gilead Sciences Announces Notification of ANDA Filing for Viread
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc.(Nasdaq: GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and...
|
|
|
Gilead Sciences Announces Notification of ANDA Filing for Viread
FOSTER CITY, Calif.Gilead Sciences, Inc. (Nasdaq:GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration ...
|
|
|
Gilead Sciences Announces Notification of ANDA Filing for Viread
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); FOSTER CITY, Calif.- (Business Wire) Gilead Sciences, Inc. (Nasdaq:GILD) today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an...
|
